health news today obesity drugs glp-1 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Alarming rise in weight loss

While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said

ONeil, J

[DOI] [PubMed] [Google Scholar] 66.Lee M.M.Y., Sattar N., Pop-Busui R., Deanfield J., Emerson S.S., Inzucchi S.E., Mann J.F.E., Marx N., Mulvagh S.L., Poulter N.R

Recent research suggests GLP-1 therapy may help

Nanoformulation for enhanced drug delivery and better patient compliance